VC-backed Imara goes public
Imara, a developer of new treatments for patients suffering from rare inherited genetic disorders of hemoglobin, has raised $75.2 million for its IPO after pricing its 4.7 million shares at $16 per share.
Imara, a developer of new treatments for patients suffering from rare inherited genetic disorders of hemoglobin, has raised $75.2 million for its IPO after pricing its 4.7 million shares at $16 per share.
Copyright PEI Media
Not for publication, email or dissemination